The project was commissioned by the European Medicines Agency (EMA). A total of 22 European organisations are involved. The Dutch contribution is significant, as UMC Utrecht, Utrecht University, RIVMNational Institute for Public Health and the Environment , the Netherlands Pharmacovigilance Centre Lareb and research institute PHARMO are contributing to ACCESS. The project is led by UMC Utrecht and Utrecht University.
The development of a vaccine normally takes 10 to 15 years. Because of the COVID-19 pandemic, the aim is to develop a vaccine within one year. The ACCESS project will help to prepare Europe for this undertaking.
RIVM is contributing to the feasibility analysis of an EU structure for COVID-19 vaccine monitoring, in collaboration with Lareb.